alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › potency

potency

3 studies tagged potency, dated 2013-09-26 to 2023-02-26. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Site-specific amino acid D-isomerization of Tau R2 and R3 peptides changes the fibril morphology, resulting in attenuation of Tau aggregation inhibitor potency 2023-02-26
  2. Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency 2017-05-05
  3. Structural determinants of Tau aggregation inhibitor potency 2013-09-26

Studies

3 studies carry this tag.

Date range

2013 to 2023

Top journals

  • Biochemical and biophysical research communications 1
  • Molecular neurodegeneration 1
  • The Journal of biological chemistry 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Site-specific amino acid D-isomerization of Tau R2 and R3 peptides changes the fibril morphology, resulting in attenuation of Tau aggregation inhibitor potency

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Biochemical and biophysical research communications 2023-02-26 Drug development

    Tau, a microtubule-binding protein, is a major component of neurofibrillary tangles in the brains of Alzheimer's disease patients.

  2. Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Molecular neurodegeneration 2017-05-05 Drug development

    These findings suggest that Armanezumab could be therapeutic in clinical studies for treatment of AD.

  3. Structural determinants of Tau aggregation inhibitor potency

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Journal of biological chemistry 2013-09-26 Drug development

    Small-molecule Tau aggregation inhibitors are under investigation as potential therapeutic agents against Alzheimer disease.

All topic tags with their study counts